Clinical trials: Oropharyngeal Squamous Cell Cancer
Head and Neck Cancer
Blood Sample Analysis in Predicting Overall Survival in Patients With Recurrent or Metastatic Head and Neck Cancer
RATIONALE: Studying samples of blood in the laboratory from patients with cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00898911
- Testing
- matrix-assisted laser desorption/ionization time of flight mass spectrometry
- Volunteers
- 30 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Neck Squamous Cell Carcinoma of Unknown Primary, Recurrent Hypopharyngeal Squamous Cell Carcinoma
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
This randomized phase III trial studies chemotherapy to see how well it works with or without bevacizumab in treating patients with head and neck squamous cell carcinoma that has come back (recurrent) or that has spread to other…
- Conditions
- Neck Squamous Cell Carcinoma of Unknown Primary, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma
- Trial name
- NCT00588770
- Testing
- Bevacizumab, Carboplatin, Cisplatin
- Where
- 779 sites in United States, Puerto Rico and 1 more
- Volunteers
- 403 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer
Radiation Therapy Plus Fludarabine in Treating Patients With Locally Advanced Cancer of the Mouth, Pharynx, or Larynx
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00004246
- Testing
- Fludarabine Phosphate, Radiation Therapy (RT)
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Squamous Cell Carcinoma of the Hypopharynx
Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer
This phase II trial studies how well sorafenib works with carboplatin and paclitaxel in treating participants with head and neck squamous cell cancer that has spread to other parts of the body or that has come back.
- Conditions
- Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Squamous Cell Carcinoma of the Hypopharynx, Metastatic Squamous Cell Carcinoma of the Larynx, Metastatic Squamous Cell Carcinoma of the Oral Cavity
- Trial name
- NCT00494182
- Testing
- Carboplatin, Paclitaxel, Sorafenib
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- M.D. Anderson Cancer Center
Oropharyngeal Squamous Cell Carcinoma
Risk Adapted De-Intensification of Radio-Chemotherapy for Oropharyngeal Squamous Cell Carcinoma
This study builds on the results of several prior studies that we have been involved with to test the hypothesis that Risk-Adapted De-Intensification of Radiation Therapy and chemotherapy based on HPV subtype, plasma circulating…
- Trial name
- NCT05268614
- Testing
- Radiation therapy, Cisplatin
- Where
- 3 sites in United States
- Volunteers
- 250 people
- Sponsor
- University of Florida
Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer
This phase II trial tests the addition of chemotherapy, with carboplatin and paclitaxel, or chemo-immunotherapy, with carboplatin, paclitaxel and cemiplimab to standard salvage surgery followed by post operative radiation therapy…
- Conditions
- Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Locally Recurrent Head and Neck Squamous Cell Carcinoma, Locally Recurrent Hypopharyngeal Squamous Cell Carcinoma
- Trial name
- NCT07195734
- Testing
- Biospecimen Collection, Carboplatin, Cemiplimab
- Where
- 115 sites in United States
- Volunteers
- 180 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer
Cisplatin, Bevacizumab, and Intensity-Modulated Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00423930
- Testing
- bevacizumab, cisplatin, conventional surgery
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Head and Neck Cancer, Squamous Cell Carcinoma
Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)
The NeoScorch HN study is a single institution multisite phase II trial including 3 cohorts of 25 patients each for patients with newly diagnosed locoregionally advanced, histologically confirmed, head and neck cancer eligible…
- Conditions
- Head and Neck Cancer, Squamous Cell Carcinoma, Oral Cavity Cancer, Oropharyngeal Cancer
- Trial name
- (NeoScorch HN) (NCT07209189)
- Testing
- Toripalimab + Chemotherapy, Toripalimab, Chemoradiotherapy or radiation
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Carcinoma, Squamous Cell of Head and Neck, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck
This research study is evaluating a drug called buparlisib (BKM120) as a possible treatment for locally advanced head and neck squamous cell cancer.
- Conditions
- Carcinoma, Squamous Cell of Head and Neck, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Hypopharyngeal Cancer, Early Invasive Cervical Squamous Cell Carcinoma
- Trial name
- NCT02113878
- Testing
- BKM120, Cisplatin, Intensity-modulated radiotherapy (IMRT)
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Dana-Farber Cancer Institute
CDKN2A-p16 Positive, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer
This phase II trial studies how well alpelisib works in treating participants with human papillomavirus(HPV)-associated stage I-IVA head and neck cancer that can be removed by surgery.
- Conditions
- CDKN2A-p16 Positive, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Stage I Oropharyngeal Squamous Cell Carcinoma AJCC V7, Stage II Oropharyngeal Squamous Cell Carcinoma AJCC V7
- Trial name
- NCT03601507
- Testing
- Alpelisib, Laboratory Biomarker Analysis, Pharmacodynamic Study
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Arizona
Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck
A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers
The purpose of this study is to test the safety and tolerability of chemotherapy and radiation in combination with the investigational study drugs zimberelimab (AB122) and etrumadenant (AB928) in subjects with a locally advances…
- Conditions
- Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck, Oral Cavity Squamous Cell Carcinoma, Oral Cavity Cancer
- Trial name
- PANTHEoN (NCT04892875)
- Testing
- Zimberelimab, Etrumadenant, Cisplatin
- Sponsor
- Jennifer Choe
Head and Neck Cancer
Blood Proteins in Predicting Treatment Benefit in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer
RATIONALE: Studying samples of blood in the laboratory may help doctors learn more about cancer. It may also help doctors predict how well patients will respond to treatment.
- Trial name
- NCT00896675
- Testing
- proteomic profiles
- Where
- 3 sites in United States
- Volunteers
- 352 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Head and Neck Cancer
NBTXR3 and Radiation Therapy in Treating Patients With Locally Advanced SCC of the Oral Cavity or Oropharynx
RATIONALE: Cancers of the oral cavity represent 30% of head and neck carcinomas in the western world. The oropharynx is the posterior continuation of the oral cavity and connects with the nasopharynx (above) and laryngopharynx…
- Trial name
- NCT01946867
- Testing
- NBTXR3 activated by IMRT
- Where
- 20 sites in France, Hungary and 2 more
- Volunteers
- 75 people
- Sponsor
- Nanobiotix
Head and Neck Cancer
Cisplatin Plus Gemcitabine in Treating Patients With Advanced Squamous Cell Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003264
- Testing
- cisplatin, gemcitabine hydrochloride
- Where
- 12 sites in United States
- Volunteers
- 22 people
- Sponsor
- Fox Chase Cancer Center
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Compartmentalized Postoperative Radiotherapy in Head and Neck Cancer
COMPORT is a multicenter phase II clinical trial evaluating a personalized approach to postoperative radiotherapy in patients with head and neck squamous cell carcinoma (HNSCC).
- Conditions
- Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma
- Trial name
- COMPORT (NCT07058805)
- Testing
- Compartmentalized Postoperative Radiotherapy
- Where
- 3 sites in Switzerland
- Volunteers
- 50 people
- Sponsor
- Olgun Elicin
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With HPV Positive, KRAS-Variant Stage III-IV Oropharyngeal Squamous Cell Carcinoma
This phase II trial studies how well radiation therapy and cisplatin with or without cetuximab works in treating patients with human papillomavirus (HPV) positive, KRAS-variant stage III-IV oropharyngeal squamous cell carcinoma.
- Conditions
- Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, KRAS Protein Variant, Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- Trial name
- NCT04106362
- Testing
- Cetuximab, Cisplatin, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Squamous Cell Carcinoma of the Oral Cavity and Oropharynx
A Study Evaluating the Contribution of Non-Coplanar Beam Arrangement in Reducing Toxicity in Radiotherapy for Upper Aerodigestive Tract Cancers
Cancers of the upper aerodigestive tract (UADT) are frequently treated with external beam radiotherapy, either alone or in combination with chemotherapy.
- Trial name
- BaReTox (NCT07413627)
- Testing
- Coplanar External Beam Radiotherapy, Non-Coplanar External Beam Radiotherapy
- Where
- France
- Volunteers
- 70 people
- Sponsor
- Centre Georges Francois Leclerc
Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells.
- Conditions
- Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer, Bone Metastases, Carcinoma of the Appendix
- Trial name
- NCT00004074
- Testing
- recombinant interleukin-12, ABI-007/carboplatin/trastuzumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Oropharyngeal Cancer, Human Papillomavirus
Human Papillomavirus (HPV) Oral Transmission Study in Partners Over Time
This research is being done to understand more about a sexually transmitted virus called Human papillomavirus (HPV) in people with oropharyngeal cancer and their partners.
- Trial name
- HOTSPOT (NCT01342978)
- Where
- 4 sites in United States
- Volunteers
- 242 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Head and Neck Cancer
Head & Neck Cancer Survivorship: Physical and Functional Status
RATIONALE: Early physical therapy may be effective in improving range of motion of the neck and shoulders in head and neck cancer survivors who are undergoing chemotherapy and radiation therapy.
- Trial name
- NCT00751816
- Testing
- systemic chemotherapy, survey administration, adjuvant therapy
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- Vanderbilt University